ジャディアンスの市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

ジャディアンス（一般名：エンパグリフロジン）は主に、腎臓でのグルコース再吸収を担う輸送体であるSGLT2の阻害薬です。2型糖尿病治療薬として初めて、数ヶ国で心血管疾患による死亡リスク低減のデータが添付文書に記載されています。エンパグリフロジンは、腎臓におけるグルコースの再吸収を阻害し、尿中へのグルコース排泄量を増加させることにより血糖値を低下させます。作用時間は比較的長く、1日1回の投与で済みます。作用機序がグルコースの腎排泄に依存しているため、急性腎障害の場合には投与を控える、あるいは慢性腎疾患に罹患した場合には投与を中止する可能性があります。

現在、企業はフェーズ3（EMPACT-MI）調査を実施中です。EMPACT-MI試験（EMPAgliflozin for the prevention of chronic heart failure and mortality after an AMI）は、急性心筋梗塞で入院した成人患者を対象に、ジャディアンスの有効性と安全性を検討する多施設共同無作為化盲検プラセボ対照試験で、2023年にデータが得られる予定です。本試験は、SGLT2阻害薬の中でもっとも広範かつ包括的なEMPOWER臨床試験プログラムの一部であり、ジャディアンスの心・腎・代謝疾患全般にわたる人々の生活に対する影響を検討するものです。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）における心筋梗塞向けジャディアンスについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 心筋梗塞におけるジャディアンスの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 ジャディアンス市場の評価

• 心筋梗塞におけるジャディアンスの市場見通し
• 主要7市場の分析
  • 主要7市場の心筋梗塞向けジャディアンスの市場規模
• 市場の分析：国別
  • 米国の心筋梗塞向けジャディアンスの市場規模
  • ドイツの心筋梗塞向けジャディアンスの市場規模
  • 英国の心筋梗塞向けジャディアンスの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: JARDIANCE, Clinical Trial Description, 2023
• Table 2: JARDIANCE, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: JARDIANCE Market Size in the 7MM, in USD million (2019-2032)
• Table 6: JARDIANCE Market Size in the US, in USD million (2019-2032)
• Table 7: JARDIANCE Market Size in Germany, in USD million (2019-2032)
• Table 8: JARDIANCE Market Size in France, in USD million (2019-2032)
• Table 9: JARDIANCE Market Size in Italy, in USD million (2019-2032)
• Table 10: JARDIANCE Market Size in Spain, in USD million (2019-2032)
• Table 11: JARDIANCE Market Size in the UK, in USD million (2019-2032)
• Table 12: JARDIANCE Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: JARDIANCE Market Size in the 7MM, USD million (2019-2032)
• Figure 2: JARDIANCE Market Size in the United States, USD million (2019-2032)
• Figure 3: JARDIANCE Market Size in Germany, USD million (2019-2032)
• Figure 4: JARDIANCE Market Size in France, USD million (2019-2032)
• Figure 5: JARDIANCE Market Size in Italy, USD million (2019-2032)
• Figure 6: JARDIANCE Market Size in Spain, USD million (2019-2032)
• Figure 7: JARDIANCE Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: JARDIANCE Market Size in Japan, USD million (2019-2032)

"JARDIANCE Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JARDIANCE for myocardial infarction in the seven major markets. A detailed picture of the JARDIANCE for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the JARDIANCE for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary:

JARDIANCE (Empagliflozin) is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for glucose re-absorption in the kidney. It is marketed under the brand name JARDIANCE and is the first type 2 diabetes medicine to include cardiovascular death risk reduction data on the label in several countries. Empagliflozin lowers blood glucose levels by preventing glucose re-absorption in the kidneys and increasing the amount of glucose excreted in the urine. It has a relatively long duration of action requiring only once-daily dosing. As its mechanism of action is contingent on the renal excretion of glucose, empagliflozin may be held in cases of acute kidney injury and/or discontinued in patients who develop chronic renal disease.

Currently, the company is conducting a Phase III (EMPACT-MI) study. EMPACT-MI (EMPAgliflozin for the prevention of chronic heart failure and mortality after an AMI) is a streamlined, randomized, blinded, placebo-controlled, multicenter trial exploring the efficacy and safety of JARDIANCE in adults hospitalized with an acute MI with data anticipated in 2023. The trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of JARDIANCE on people's lives across the spectrum of cardio-renal-metabolic conditions.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the JARDIANCE description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on JARDIANCE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JARDIANCE research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around JARDIANCE.
• The report contains forecasted sales of JARDIANCE for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for JARDIANCE in myocardial infarction.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JARDIANCE Analytical Perspective by DelveInsight

• In-depth JARDIANCE Market Assessment

This report provides a detailed market assessment of JARDIANCE for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• JARDIANCE Clinical Assessment

The report provides the clinical trials information of JARDIANCE for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JARDIANCE dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to JARDIANCE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JARDIANCE in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of JARDIANCE from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JARDIANCE in myocardial infarction.

Key Questions:

• What is the product type, route of administration and mechanism of action of JARDIANCE?
• What is the clinical trial status of the study related to JARDIANCE in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JARDIANCE development?
• What are the key designations that have been granted to JARDIANCE for myocardial infarction?
• What is the forecasted market scenario of JARDIANCE for myocardial infarction?
• What are the forecasted sales of JARDIANCE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to JARDIANCE for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

Table of Contents

1. Report Introduction

2. JARDIANCE Overview in myocardial infarction

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. JARDIANCE Market Assessment

• 5.1. Market Outlook of JARDIANCE in myocardial infarction
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of JARDIANCE in the 7MM for myocardial infarction
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of JARDIANCE in the United States for myocardial infarction
  • 5.3.2. Market Size of JARDIANCE in Germany for myocardial infarction
  • 5.3.3. Market Size of JARDIANCE in France for myocardial infarction
  • 5.3.4. Market Size of JARDIANCE in Italy for myocardial infarction
  • 5.3.5. Market Size of JARDIANCE in Spain for myocardial infarction
  • 5.3.6. Market Size of JARDIANCE in the United Kingdom for myocardial infarction
  • 5.3.7. Market Size of JARDIANCE in Japan for myocardial infarction

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options